Table 1.
Categories | Symptoms and immune correlates (# of patients) | CTCAE grade |
---|---|---|
Neurocognitive and psychological | Memory impairment (6) | 1–2 |
Impairment in attentional processing (6) | 1–2 | |
Mild-moderate depression (3) | 1–2 | |
Post-traumatic stress disorder (2) | 2 | |
Anxiety requiring psychotherapy (4) | 1–3 | |
Headaches (5) | 1–2 | |
Blurred vision (5) | 1 | |
Autoimmune and inflammatory | Mild neutropenia (3) | 1 |
Arthralgias—knees, hands, back (6) | 1 | |
Positive auto-antibodies (4) | 1 | |
Ischemic extremities (1) | 3 | |
Raynaud’s phenomenon (1) | 1 | |
Immune mucosal barrier function | Diarrhea and ↑ γδT cells (3) | 1–2 |
Skin dryness and ↑sensitivity (3) | 1–2 | |
Pruritus (1) | 1–2 | |
Peripheral blood eosinophilia (3) | 1 | |
↑ Serum IgE (4) | 1 | |
Benign lipomas/angiolipomas (1) | 2 | |
Immune cell subsets and cytokines | Gradual recovery of DC over 1 month (6) | 1 |
Low-normal total CD4+ T cells (5) | 1 | |
Low-normal total CD8+ T cells (6) | 1 | |
↑ sustained naïve CD8+ T cells (5) | 1 | |
↓ naïve CD4+ T cells over time (5) | 1 | |
↓ memory CD4+ T cells over time (4) | 1 | |
↓ memory CD8+ T cells over time (4) | 1 | |
Normal Tregs with circannual cycle (6) | 1 | |
Vβ repertoire normal (6) | – | |
Normal immune responses in vitro (6) | – | |
↑ sustained erythropoietin level for 3 months (1) | 1 | |
↑ cytokine response from 3 months (1) | 1 | |
IL-17 differences (6) | 1 |
CTCAE common terminology criteria for adverse events, version 4.03